Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132013 | 0.89 | KCNH2 (0.49) | KCNH2HRH3LTA4HSMN1; SMN2LSS | |
| SCHEMBL14320600 | 0.88 | NOS3 (0.47) | NPC1RAB9AKCNH2HRH3LTA4H | |
| SCHEMBL20410952 | 0.83 | KCNH2 (0.43) | KCNH2HRH3LTA4HSMN1; SMN2LSS | |
| SCHEMBL10520360 | 0.81 | KCNH2 (0.48) | KCNH2HRH3LTA4HSMN1; SMN2LSS | |
| SCHEMBL20410837 | 0.81 | KCNH2 (0.44) | KCNH2HRH3LTA4HSMN1; SMN2LSS | |
| SCHEMBL9475161 | 0.81 | KCNH2 (0.44) | KCNH2HRH3LTA4HSMN1; SMN2LSS | |
| SCHEMBL1817200 | 0.79 | LSS (0.51) | KCNH2HRH3LTA4HALDH1A1KDM4E | |
| SCHEMBL5464687 | 0.79 | NPC1 (0.43) | NPC1RAB9AKCNH2HRH3LTA4H | |
| SCHEMBL961792 | 0.79 | KCNN4 (0.44) | KCNH2HRH3LTA4HALDH1A1HPGD | |
| SCHEMBL9181791 | 0.79 | KCNH2 (0.43) | KCNH2HRH3LTA4HSMN1; SMN2LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6433116-B1 | — | — | None | — | — | US | disclosed |
| JP-4159269-A | — | — | None | — | — | JP | disclosed |
| CN-116144176-B | Polyimide composition, film, preparation method and application thereof | 山东华夏神舟新材料有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116144176-A | Polyimide composition, film, preparation method and application thereof | 山东华夏神舟新材料有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11529760-B2 | Polymeric materials and articles manufactured there from | THE PROCTER & GAMBLE COMPANY (US) | 2022-12-20 | — | — | US | disclosed |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| EP-3204009-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| US-6433116-B2 | CROSSLINKING; COATINGS, INKS, VARNISHES, SURFACE TREATMENT | S. C. JOHNSON COMMERCIAL MARKETS, INC. | 2002-08-13 | — | — | US | disclosed |
| WO-2002004441-A1 | MULTIFUNCTIONAL COUPLING AGENTS WITH CYCLIC IMINOESTER AND IMINOETHER GROUPS, METHOD FOR PRODUCING THE SAME AND USE THEREOF | INSTITUT FÜR POLYMERFORSCHUNG DRESDEN E.V. (DE) | 2002-01-17 | — | — | WO | disclosed |
| US-20010018516-A1 | Oxazoline or oxazine acetoacetate aqueous coating compositions | BASF CORPORATION | 2001-08-30 | — | — | US | disclosed |
| US-6235901-B1 | CAN BE POLYMERIZED AND/OR COPOLYMERIZED BY CATONIC POLYMERIZATION; CAN BE CROSSLINKED AND ARE USEFUL IN COATINGS, INKS, OVERPRINT VARNISHES, AND SURFACE TREATMENT APPLICATIONS. | S. C. JOHNSON COMMERCIAL MARKETS, INC. | 2001-05-22 | — | — | US | disclosed |
| WO-2000068212-A1 | OXAZOLINE OR OXAZINE ACETOACETATE AQUEOUS COATING COMPOSITIONS | S. C. JOHNSON COMMERCIAL MARKETS, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| EP-0320032-B1 | Pyridizinamine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-01-18 | — | — | EP | disclosed |
| US-5231184-A | Viricide intermediate | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-07-27 | — | — | US | disclosed |
| JP-H04159269-A | NEW OXAZOLINE COMPOUND | ASAHI DENKA KOGYO KK | 1992-06-02 | — | — | JP | disclosed |
| US-5106973-A | Viricide intermediates | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-04-21 | — | — | US | disclosed |
| US-4992433-A | Viricides | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529760-B2 | Polymeric materials and articles manufactured there from | ALG3, CD68, VCL | NPC1 3857/4885RAB9A 2829/4885KCNH2 362/4885 |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | NPC1 66/4885RAB9A 3766/4885KCNH2 4772/4885 |
| US-20010018516-A1 | Oxazoline or oxazine acetoacetate aqueous coating compositions | ITGB7, DNMT3A, KAT7 | NPC1 3046/4885RAB9A 2992/4885KCNH2 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.